PubMed Health⌕ Search

PubMed · 11844368

Reproductive issues from the Islamic perspective.

Abstract

The Islamic faith is regarded by its followers, Muslims, as a complete way of life. A multitude of nationalities practise Islam and also various sects, and as a result there are various interpretations of Qur'anic guidance relating to almost every matter. Only a fully qualified jurist of the highest rank can issue edicts on problems that are not already clearly addressed in the Qur'an. This applies to contemporary issues and any Muslim is at liberty to debate and dialogue with the religious leader to obtain a ruling on a specific question. Marriage is described as half the faith in Islam and to have children is seen as a great blessing. There is no religious objection to an infertile married couple pursuing any form of infertility treatment including in vitro fertilization, surgical sperm retrieval and micro-assisted conception methods. However, there must be strict control to ensure that the gametes belong to the husband and wife. This relationship is described as 'halal' (permitted), whereas any union of gametes outside a marital bond, whether by adultery or in the laboratory, is 'haraam' (forbidden). Therefore, donor sperm pregnancies are strictly forbidden in all schools of Islamic law. The advent of ovum donation and surrogacy has led some Islamic scholars to allow this procedure between co-wives thereby avoiding the 'haraam' relationship between sperm and egg, but there is still debate on the definition of the mother. Similarly, treating any other situation outside a marriage relationship, for example fertilization of an ovum from cryopreserved sperm after divorce of the couple or death of the husband would be 'haraam' and strictly forbidden. The Qur'anic guidance is quite clear that the couple can pursue all permitted treatments but may need to accept that they may not achieve a pregnancy. Adoption is encouraged in Islam with the specific rule that the child must be able to identify its biological father by keeping his name. It must be emphasized that Muslims will vary on their degree of adherence to the faith and the practitioner should present all the options to the couple without assuming which treatments they will or will not accept.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Fatima A. Husain. 2000. Reproductive issues from the Islamic perspective.. https://doi.org/10.1080/1464727002000198831

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗